Geropharm

GEROFARM Group of Companies, which is part of the TOP-20 of Russian pharmaceutical companies, Russian manufacturer of full-cycle human genetically engineered insulins Rinsulin. This insulin is produced from a domestic substance, the quality of which was highly appreciated by three independent certified European laboratories - Proteome Factory AG Berlin, Prolytic GmbH Frankfurt am Main, Labor L + S AG. The company produces the domestic neuroprotector Cortexin, used in the complex therapy of a wide range of nervous disorders, the original domestic retinoprotector Retinalamine, which has proven its effectiveness, in particular, in the therapy of primary open-angle glaucoma, diabetic retinopathy, central retinal dystrophy and myopic disease, as well as an effective drug for the basic therapy of moderate to severe senile dementia - Memantinol, enabling preservation of cognitive functions, enhancing self-care skills and normalizing behavior.

History

2024: Insulin Technology Supplies to Venezuela

In Venezuela, the production of insulin using Russian technology has begun. This was announced on June 20, 2024 by the Russian Ambassador to the Bolivarian Republic Melik-Bagdasarov. This step was the result of a joint program between Russia and Venezuela aimed at ensuring stable supplies of a vital drug for patients with diabetes.

For the first time in five years, a large consignment of insulin from Geropharm by sea was delivered to Venezuela. The ambassador noted that the Russian company Geropharm is actively cooperating with the Venezuelan Ministry of Health, and in the future it is planned to launch a production line for Venezuelan insulins based on Russian technology.

source = Geropharm

Thanks to the efforts of our leaders, President Russia Vladimir Putin and President of Venezuela Nicolas Maduro, within five years we are implementing a joint program with the Venezuelan Ministry of Health to supply insulin from our Russian company Geropharm, "said Sergei Melik-Bagdasarov.

According to TASS, Geropharm acquired laboratory and production equipment for the Espromed Bio plant in Venezuela. According to plans, in 2025, Espromed Bio, after modernization, will begin to produce insulin from substances of the Russian company. More than 3 million vials are projected to be produced annually, which will close 85% of the needs of the state health care system and 15% of the commercial sector in Venezuela.

As part of the long-term agreement, designed for the period from 2022 to 2026, it is envisaged to modernize the capacities of Espromed Bio and transfer the technology for the production of finished dosage forms of genetically engineered human insulins (GIIC). From 2024, 100% of GIICHs in vials will be produced in Venezuela from the Geropharma substance, and supplies of analogues of insulin and GIICHs in cartridges will continue from Russia.^[1]

2023

Geropharm bought 49% of AZT Group

In early December 2023, it became known about the sale of 49% of the AZT group to the Russian insulin manufacturer Geropharm. Its participants did not disclose the financial and other parameters of the transaction. Read more here.

Investment of 163 million rubles in the expansion of the production of pen syringes in the Moscow region

The Russian pharmaceutical company Geropharm has invested 163 million rubles in a project to increase the production of insulin pen syringes at an enterprise in Obolensk near Moscow. This was announced in August 2023 by the press service of the Ministry of Housing Policy of the Moscow Region.

It is specified that the funds were raised for the reconstruction of production in the village of Obolensk, the city district of Serpukhov. To organize a new site for the assembly of syringe pens with insulin, the building of the finished product warehouse was converted. An additional automated line has been installed at the facility with an area of ​ ​ more than 2 thousand square meters. meters have been installed, which will allow collecting 7 million pen syringes per year. The production capacity of the enterprise will increase to 21 million injectors annually. 17 jobs created.

Geropharm invested 163 million rubles in a project to increase the production of insulin syringes-pens

The project is part of a large-scale reconstruction of the enterprise in Obolensk with a total check of 1.4 billion rubles. It is assumed that 900 million rubles will be invested in the purchase of equipment for the production and spill of a drug, and more than 500 million rubles in construction work.

Packaging and assembly equipment is planned to be supplied from South Korea and Germany, for the spill - in China. It is expected that after the commissioning of all lines, the capacity of the enterprise will increase by 46 million bottles and 14 million pen syringes per year.

Initially, Geropharm purchased Rinsapen syringe pens for insulin from the Swiss Ypsomed, but later the company entered into the registration certificate for Rinsapen II a version of the syringe pen localized at the facilities of the plant in the Moscow Region. By August 2023, Geropharm produces insulin and analogues for subcutaneous administration in Rinastra II syringe pens, and also supplies Ransapen II syringe pens for subcutaneous administration of insulin drugs and insulin analogs in 1 unit increments.^[2]

2022

Increase in annual insulin production by 1.7 times

In 2022, Geropharm released 7.4 million packages of insulin, which is 64.8% more than a year earlier. The company reported this on May 17, 2023.

The growth in production at Geropharm was explained by an increase in the share of Russian enterprises in the Russian insulin market and the development of the export direction in companies. Geropharm is considering the supply of products to Latin America, Southeast Asia, North Africa, the Gulf countries and the Middle East in the future, the company's press service said. They also added that when planning the expansion of production, Geropharm proceeds from the risk of stopping the supply of foreign drugs to Russia.

"Geropharm" increased the annual production of insulin 1.7 times

Earlier, Geropharm and Rosselkhozbank entered into an investment deal for 1.8 billion rubles. The funds will be used to modernize the production of insulin substance in the city of Pushkin and create a new packaging and bottling area for medicines in the village of Obolensk, Moscow Region. As a result of the project, the production of the substance will grow 2 times, and the production of finished medicines will be increased by 46 million vials per year. Commissioning of the facilities is scheduled until the end of 2023. An increase in productivity for the production of substance and finished medicines will contribute to the development of import substitution of vital drugs, noted in "Geropharm."

They also added that contracts for equipment for the project were concluded with suppliers from friendly states, which levels the risks of disruption of supplies due to restrictions and sanctions. In the future, service will be carried out by company specialists.

According to data for 2022, Geropharm calls itself the leader in the Russian insulin market in the segments of its presence. All stages of production are carried out at the company's own production facilities in Russia.^[3]

Lawsuit for 260 million rubles from the developer of EpiVacCorona

On July 22, 2022, Vector-BiAlgam JSC, one of the manufacturers of the EpiVacCorona COVID-19 vaccine, filed a lawsuit against Geropharm demanding to recover 260 million rubles from it. What time did the plaintiff estimate the losses that he claims to have suffered in connection with the receipt of low-quality products.

Writes about the lawsuit Kommersant"" with reference to the file of arbitration cases. According to the newspaper, Geropharm produced one of the key components of Epivakkorona - the carrier protein with which peptides are combined. In June 2021, Vector-BiAlgam ordered this protein from the company, the amount of the contract and the volume of the order were not disclosed. The file of cases says that in March 2022, Geropharm filed a lawsuit against Vectro-BiAlgas demanding an additional payment of 203 million rubles for the supply.

The developer of Epivakkorona demands to reimburse 260 million rubles of the supplier of low-quality components

According to the contract, the quantity of actually delivered goods is determined on the basis of data on the recoverable volume and protein content in the batch. These data are recorded by the parties by a special act. Vector-BiAlgam did not pay for the protein delivered in September and October 2021, which confirms the reconciliation act.

The defendant during the trial stated that the goods delivered were of poor quality. In this regard, Vector-BiAlgam considered that an overpayment had formed on the side of Geropharm. The plaintiff admitted that he knew about the poor-quality squirrel, but it was not placed in the controversial parties.

Geropharm claims that all products that went to the production of the vaccine were carefully checked and destroyed at the slightest suspicion.

In return, new supplies of raw materials were made, the quality of which passed the appropriate check and was accepted. As a result, not a single batch of raw materials, the quality of which could arouse suspicions, was allowed to produce the finished EpiVacCorona vaccine, the press service said.[4]

2015

The project will allow the industrial production of innovative insulin drugs with high import-substituting potential. In addition, it is planned to establish the production of new ready-made medicines for the treatment of epilepsy, dementia, strokes and pain caused by damage to the nervous system.

The company will create a technological complex for the production of substances for injectable drugs, including purified insulin substance. Currently, more than 85% of the demand of the Russian market for injection lyophilized (soluble) forms of the GMP class is covered by imported supplies.

The implementation of the project will significantly reduce the cost of production by organizing a production cycle at one enterprise. This will significantly reduce the sales price of the drug compared to foreign counterparts. Export opportunities include the CIS countries, the Middle East, North Africa, and Southeast Asian countries.

The company has already invested 163.5 million rubles in the project, plans to invest another 2,068,1 million rubles, of which 500 million rubles may amount to preferential loan financing from the Industrial Development Fund. It is planned to create 221 workplaces.

Notes